Powering New Possibles
in Cell Therapy Manufacturing

We are developing a groundbreaking device platform for autonomous and miniaturized cell therapy production, significantly increasing capacity and reducing costs


Facts about cell therapy

85%

complete remission in r/r ALL patients
after a cell therapy treatment

Source

44%

still cancer free, four years after a single infusion of a cell therapy

Source

3%

of all eligible cancer patients receive a cell therapy

320K

price in EUR of a cell therapy
Kymriah, Germany 2020


Vision

Motivation

Cell Therapy transformed cancer treatment. Sarcura will transform cell therapy manufacturing.

Daniela Buchmayr, MBA
CEO


Sarcura's Solution

Technology

Autonomy

Control intelligence enables the platform to autonomously perform processing and product control for each batch without human interaction

Miniaturization

Semiconductor chip technology and microfluidics enable processing with an unprecedentedly small footprint and cell-level certainty

Modularity

Functional modules allow for individual process designs for various cell types, offering conceptual flexibility


Related News

Journal

Supported by

Partners